BDSA and Management Science Associates, Inc. (MSA), a provider of analytics and data-driven solutions for Fortune 500 companies, have entered into a strategic alliance to offer technical support and industry cross-analysis between BDSA's cannabis industry clients and MSA's clients in the CPG, health care and government sectors.

One of the key advantages of this collaboration is MSA's patented and HIPAA-compliant methodology for de-identifying protected health information. Combined with BDSA's comprehensive data, this methodology enables statistical analysis of consumers and delivers groundbreaking insights into the intersection of purchasing cannabis and pharmaceuticals for health care needs. 

Statistically significant cannabis consumption and real-world health care data will be combined to identify the impact of cannabis consumption on consumer health and purchasing.

“Our collaboration with MSA will revolutionize our clients' understanding of how cannabis addresses diverse consumer needs,” said Roy Bingham, co-founder and CEO of BDSA. “With half the population having consumed cannabis in the past six months, this is no longer a niche category only of interest to those within the industry. This partnership will provide actionable, revenue-driving audience, sales impact and forecasting opportunities to companies inside and outside the cannabis industry.”

Through this alliance, BDSA and MSA resolve critical issues for their clients. Manufacturers contemplating entry into the cannabis industry often face the challenge of limited visibility into cannabis dispensary sales. The integration of BDSA's data with MSA's reporting and analytical capabilities allows manufacturers to target products to consumers.

“We are excited to partner with BDSA to expand our data portfolio to include critical sales insights from cannabis dispensaries,” said Stephen Gongaware, executive vice president of business development at MSA. “This collaboration will benefit companies both inside and outside the cannabis industry, helping them navigate this rapidly evolving landscape. Our joint analysis across datasets will help size new audiences and revenue opportunities and our ongoing study will shed light on the impact of cannabis purchasing on pharma, tobacco and alcohol audiences, usage and purchasing.”

By merging BDSA and MSA data and analytics, expanded insights are made available, including cross-category purchasing and impact, medical audience segmentations, opportunity sizing, fair share reports and longitudinal customer analytics.